Viewing Study NCT01211457

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:40 PM
Ignite Modification Date: 2026-03-07 @ 1:43 PM
Study NCT ID: NCT01211457
Status: UNKNOWN
Last Update Posted: 2019-07-16
First Post: 2010-09-27
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Sponsor: Cyclacel Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia View
None Myelodysplastic Syndromes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Sapacitabine View
None decitabine View
None venetoclax View
None elderly View
None AML View
None MDS View
None Refractory View
None relapsed View
None untreated View